Advertisement
Document › Details
Polyphor Ltd.. (7/17/18). "Press Release: Polyphor Announces Listing of New Shares Related to the Convertible Loan Facility Agreement with the Wellcome Trust (Ad-hoc Announcement)".
Organisation | Polyphor Ltd. (SIX: POLN) | |
Today | Spexis AG (SIX: SPEX) | |
Group | Spexis (Group) | |
Organisation 2 | Wellcome Trust, The | |
Product | antibody | |
Product 2 | investment banking | |
Index term | Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share | |
Person | Scott, Kalina (Polyphor 201706– CFO before Bank am Bellevue + UBS + KPMG) | |
Polyphor today announced that 15'758 new registered shares issued from the authorized capital have been listed today on SIX Swiss Exchange. In April 2018 Polyphor and the Wellcome Trust entered into an amendment agreement to the convertible loan facility agreement made available to Polyphor by the Wellcome Trust. In this amendment agreement the Wellcome Trust exercised its right to convert the outstanding loan amount in full immediately prior to the completion of the listing of Polyphor's shares. These shares have a lock-up period ending one year after the first day of trading.
For further information please contact:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com
About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel and is listed on the Swiss Stock Exchange (SIX: POLN). For more information, please visit www.polyphor.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Spexis (Group)
- [1] Spexis AG. (2/8/23). "Press Release: Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin (Ad hoc annuncement)". Allschwil....
- [2] Polyphor Ltd.. (29/10/21). "Press Release: Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting". Allschwil....
- [3] Polyphor Ltd.. (9/10/21). "Press Release: Polyphor and EnBiotix Announce Closing of Purchase Agreement of Inhaled Murepavadin by EnBiotix". Allschwil....
- [4] Polyphor Ltd.. (9/1/21). "Press Release: Polyphor and EnBiotix Announce Signing of Merger Agreement and Sale of Inhaled Murepavadin to EnBiotix". Allschwil....
- [5] Polyphor Ltd.. (10/14/20). "Press Release: Polyphor Receives CARB-X Award of up to USD 18.44 Million to Support Development of New Antibiotic Program". Allschwil....
- [6] Polyphor Ltd.. (1/23/20). "Press Release: Polyphor Appoints Gökhan Batur as Chief Executive Officer". Allschwil....
- [7] Polyphor Ltd.. (6/27/19). "Press Release: Polyphor Appoints Frank Weber as New Chief Medical and Development Officer". Allschwil....
- [8] Polyphor Ltd.. (5/17/19). "Press Release: Polyphor Announces Presentation of New Survival Data on Balixafortide at the ASCO Annual Meeting 2019". Allschwil....
- [9] Polyphor Ltd.. (4/9/19). "Press Release: Polyphor Appoints Gökhan Batur as Chief Commercial Officer". Allschwil....
- [10] Polyphor Ltd.. (9/6/18). "Press Release: Polyphor Announces Financial Results for the First Half 2018". Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top